K
want some more
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
In conclusion, sorafenib is well tolerated but has little or no antitumour activity in advanced melanoma patients as a single agent at the dose evaluated (400 mg b.i.d.).
